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Background: Obesity, a critical component of metabolic syndrome (MetS), is associated with depression. Deficiency
of brain-derived neurotrophic factor (BDNF) is involved in the mechanism of depression. We hypothesized that
weight reduction would improve depressive symptoms via increasing BDNF levels in obese men.
Methods: Male adults with obesity were enrolled in a weight-reduction program for twelve weeks. All subjects
underwent daily caloric restriction and an exercise program which was regularly assessed in group classes. Fasting
blood samples and Zung Self-Rating Depression Scale (Zung SDS) scores were collected for assessments before and
after the study.
Results: A total of 36 subjects completed this program. The average reduction in body weight was 8.4 ± 5.1 kg
(8.8 ± 5.1%, P < 0.001). Fasting serum BDNF significantly increased after the study (from 40.4 ± 7.8 to 46.9 ± 8.9 ng/ml,
P < 0.001). However, the depression symptoms, as assessed by the Zung Self-Rating Depression Scale
(Zung SDS), did not reduce significantly (P = 0.486). Divided into subgroups based on changes in BDNF, Zung
SDS scores were significantly reduced in subjects with greater BDNF increase than in those with minor BDNF change
(-3.9 ± 6.2 vs. 2.3 ± 6.7, P = 0.009). The increased percentage of BDNF was inversely correlated with the change
in Zung SDS (r = -0.380, P = 0.022). Multivariate regression analysis showed that reduction in BDNF was independently
associated with change in Zung SDS (95% confidence interval -0.315 to -0.052, P = 0.008).
Conclusion: Zung SDS only significantly improved in men with increased fasting BDNF levels after a lifestyle intervention.
Trial registration: (NCT01065753, ClinicalTrials.gov)
Keywords: Exercise, Lifestyle intervention, Obesity, Zung self-rating depression scaleIntroduction
Metabolic syndrome (MetS), a cluster of risk factors for
cardiovascular disease, is associated with several chronic
diseases and has become an important public health
concern due to its high prevalence [1-3]. Obesity is
considered a critical target for treatment due to its* Correspondence: whhsheu@vghtc.gov.tw
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reproduction in any medium, provided the orpathophysiological role in MetS [4-6]. Weight reduction
by dietary and exercise intervention can prevent several
sequential complications of MetS [7-9].
Adult obesity is also associated with intellectual
disabilities [10]. Decreased hippocampal volume and
advanced brain atrophy have been reported in subjects
with central obesity [11]. Furthermore, MetS could predict
cognitive impairment in prospective studies [12,13]. MetS
is clearly associated with dysfunction of the central
nervous system; however, the underlying factors contributing
to the pathogenesis of the central nervous system are
not well understood. It was postulated that inflammation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Several studies have also suggested that some peripheral
signals, crossing the blood brain barrier, may be involved
in neuroprotective pathways [15-17].
Brain-derived neurotrophic factor (BDNF), an important
neurotrophin in the development of neurons and the
regulation of synaptic activities, exists not only in the
central nervous system but also in the peripheral blood
with a positive correlation [18-21]. The process of learning
and memory formation are associated with the activation
of tyrosine receptor kinase B (TrkB) through the binding
of BDNF [22]. BDNF has been reported to be associated
with depression, and the severity of depression might
be affected by changes in BDNF after antidepressant
treatment [23,24].
Furthermore, BDNF helps maintain the energy homeo-
stasis that suppresses food intake and increases energy
expenditure [25,26]. Circulating BDNF was reported to be
increased in obese women, and high BDNF levels were
observed in subjects with MetS [27-29]. Conversely, low
BDNF concentrations were also observed in subjects with
obesity, MetS or diabetes [30,31]. Martin et al. [32] reported
improved cognitive function and increased circulating
BDNF in rats undergoing energy restriction. To examine
the hypothesis that an increase in circulating BDNF
concentration can improve central nervous symptoms
in men during weight reduction, a prospective study
was conducted to assess BDNF and depression score
in men with MetS after a lifestyle intervention.
Methods
Subjects
This study was conducted in the Division of Endocrinology
and Metabolism at Taichung Veterans General Hospital.
The inclusion criteria were men with MetS as defined by
the International Diabetes Federation (IDF), who fulfilled
the following conditions: central obesity with a waist
circumference greater than 90 cm, plus two or more
of the following four components: (1) triglyceride
equal to or greater than 150 mg/dL (1.7 mmol/L), (2)
high-density lipoprotein (HDL) cholesterol less than
40 mg/dL (1.0 mmol/L), (3) blood pressure equal to
or greater than 130/85 mmHg or using antihypertensive
medications and (4) fasting glucose equal to or greater
than 100 mg/dL (5.6 mmol/L) [4]. Exclusion criteria
were: (1) aged under 20 or over 75 years, (2) history
of diabetes or taking anti-diabetic medications, (3)
history of psychological disorders or medications for
schizophrenia or bipolar disorder, (4) endocrine diseases
such as thyroid or adrenal disorders, (5) acute or chronic
renal diseases with serum creatinine levels greater than
200 mmol/L, (6) alanine aminotransferase or aspartate
aminotransferase levels three times greater than the
normal upper limit, or liver cirrhosis, (7) acute or chronicinfectious diseases, (8) severe systemic diseases such as
malignant or immune disorders, (9) addiction to alcohol
or drugs, (10) taking any medication which changes
body weight, such as steroid, (11) changes in medica-
tions for hypertension, hyperlipidemia, anti-platelet or
anti-inflammation in the past month, (12) limitations
to following the regular dietary and exercise intervention
based on clinical judgment or the participant’s personal
reasons.
Procedure
All the enrolled subjects took part in a scheduled
twelve-week weight-reduction program. Each subject
received instructions from a registered dietitian on how
to maintain a 1200 Kcal/day diet, divided into 300 Kcal
at breakfast, 400 Kcal at lunch and 500 Kcal at dinner.
Subjects were required to attend eight classes of
group training in lifestyle change. The content of each
three-hour class included: (1) assessment of body weight
and diet diaries by the dietitian, (2) an educational program
for diet control, exercise promotion and target setting,
(3) a discussion among the participants, the dietitian
and doctors specializing in cardiology or endocrinology,
and (4) a 50-minute practice session with moderate aerobic
exercise under the supervision of trained instructors and
with the attendance of doctors. A reduction of 10% in basal
body weight was planned and no medication changes were
allowed during the study. The study was approved by the
Institutional Review Board of Taichung Veterans General
Hospital and written informed consent was provided by all
participants (NCT number: 01065753).
Measurements
Overnight fasting blood samples were collected at baseline
and at the end of the study for measurements of glucose,
insulin, lipids, liver enzymes, creatinine, C-reactive protein
(CRP) and BDNF. Study subjects were assessed using
the Zung Self-Rating Depression Scale (Zung SDS).
There were 20 items on the depression questionnaire,
either positive or negative, which the study subjects were
required to grade on a scale of 1 to 4. The severity score
was calculated by formula conversion [33].
Glucose, creatinine, triglyceride, cholesterol and liver
enzymes were measured by commercial kits (Beckman
Coulter, Fullerton, USA). Insulin, HDL cholesterol and
low-density lipoprotein (LDL) cholesterol levels were also
measured by commercial kits (Roche Diagnostics GmbH,
Mannheim, Germany). For quantitative evaluation of
insulin resistance, the homeostasis model assessment of
insulin resistance (HOMA-IR) index was calculated using
the following equation: fasting insulin (μIU/mL)*fasting
glucose (mmol/L)/22.5 [34]. CRP was measured by the
immunochemical assay of purified Duck IgY (ΔFc) anti-
bodies (Good Biotech Corp., Taichung, Taiwan); the mean
Table 1 The baseline data of subjects based on






(n = 18) (n = 18)
Age (year) 41±9 47±11 0.084
Body weight (kg) 95.6±13.8 98.3±11.4 0.319
BMI (kg/m2) 33.5±4.2 33.4±3.6 0.849
Waist circumference (cm) 108.1±10.4 110.0±7.8 0.288
Systolic BP (mmHg) 129±16 141±18 0.059
Diastolic BP (mmHg) 79±12 82±13 0.438
Fasting glucose (mmol/L) 5.5±0.9 5.7±0.7 0.090
Fasting insulin (μIU/ml) 15.6±5.2 22.8±14.0 0.034
HOMA IR 3.9±1.5 5.9±3.7 0.029
Triglyceride (mmol/L) 4.0±7.1 2.5±1.1 0.812
Total cholesterol (mmol/L) 5.5±1.6 5.0±0.7 0.393
LDL cholesterol (mmol/L) 3.3±0.9 3.2±0.6 0.486
HDL cholesterol (mmol/L) 1.0±0.2 1.0±0.2 0.568
Serum creatinine 81.4±12.9 81.2±16.9 0.887
AST (U/L) 28.7±10.4 34.4±11.4 0.081
ALT (U/L) 40±17 48±21 0.241
CRP (mg/L) 3.5±4.8 2.2±2.0 0.558
BDNF (ng/ml) 43.7±7.5 37.2±6.8 0.011
Zung SDS 37.3±7.1 38.0±10.4 0.646
1cutoff value: median (16.1%) of the change percentage of BDNF.
ALT = alanine aminotransferase, AST = aspartate aminotransferase,
BDNF = brain-derived neurotrophic factor, BMI = body mass index, BP = blood
pressure, CRP = C-reactive protein, HDL = high-density lipoprotein,
HOMA-IR = homeostasis model assessment of insulin resistance, LDL = low-density
lipoprotein, Zung SDS = Zung Self-Rating Depression Scale.
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and 1.4%, with an analytical sensitivity of 0.1 mg/L.
Human BDNF was measured by a commercially available
immunoassay kit (R & D Systems, Minneapolis, USA), and
the mean intra-assay and inter-assay CVs for BDNF were
4.1% and 9.0%, respectively, with an analytical sensitivity of
0.02 ng/mL. There was no significant cross-reactivity or
interference with nerve growth factor, neurotrophin-3 and
neurotrophin-4 prepared at a concentration of 50 ng/mL
in a BDNF control.
Statistics
All descriptive data were presented as mean ± standard
deviation (SD). Statistical analyses were conducted
with the non-parametric Wilcoxon Signed Rank test
to compare the difference before and after intervention.
The relationship between the change in Zung SDS and
the associated risk factors was determined by Spearman’s
correlation. A Mann-Whitney test was used to detect
the difference between the two groups. Multivariate linear
regression analysis was employed to analyze the factors
associated with the change in Zung SDS. Statistical analyses
were performed using SPSS 12.0 (Chicago, IL, USA).
Results
Of the 40 subjects with MetS enrolled for the study, 36
subjects completed the weight-reduction program. The
average weight was significantly reduced by 8.4 ± 5.1 kg
(8.7 ± 5.1%, P < 0.001). The average serum concentration
of BDNF was significantly increased at the end of the
study (from 40.4 ± 7.8 to 46.9 ± 8.9 ng/ml, P < 0.001).
However, the Zung SDS did not significantly differ from
the baseline by the end of the study (from 37.6 ± 8.8 to
36.9 ± 7.2, P = 0.486). To determine the effect of BDNF,
all subjects were equally divided into two groups based
on the percentage change in BDNF (median of 16.1%)
(Table 1). The baseline fasting insulin (P = 0.034) and
HOMA-IR (P = 0.029) were higher in subjects with a
greater BDNF increase than in those with a minor BDNF
change. Table 2 shows the characteristics of both groups
before and after the study. No significant differences
were observed in change of body weight, adipokines,
CRP or any of the MetS components between these two
groups at the end of the study. Interestingly, significant
reduction in Zung SDS in subjects with a greater BDNF
increase was found compared to those with a minor
BDNF change (-3.9 ± 6.2 vs. 2.3 ± 6.7, P = 0.008). Figure 1
shows a significant correlation between the changes in
BDNF and in Zung SDS (r = -0.380, P = 0.022). However,
change in body weight or MetS components were
not correlated with Zung SDS (Table 3). Based on
the regression model, the increase in BDNF was an
independent factor for the reduction of Zung SDS, after
adjusting for age, insulin resistance, and changes in weight.(Table 4). Furthermore, baseline BDNF seemed to be
higher in the minor BDNF change group than in the other.
However, after adjusting for the baseline BDNF levels, the
change in BDNF was still associated with the reduction in
Zung SDS (95% confidence interval between -0.355 and
0.073, P = 0.004).Discussion
In the present study, lifestyle intervention by diet
control and exercise promotion resulted in a significant
body-weight reduction in men with MetS. BDNF was
significantly increased after the weight-reduction program.
However, the mean severity of depressive symptoms
assessed by the Zung SDS did not significantly improve.
An important finding of the present study was an inverse
correlation between the changes in Zung SDS and
circulating BDNF level. Our results showed the important
role played by BDNF in improving depressive symptoms
in men with MetS during the weight-reduction process.
Nevertheless, the correlation between the reduction in
Table 2 Alteration in clinical data of subjects grouped






(n = 18) (n = 18)
Body weight (kg) -7.7±4.8* -9.1±5.4*
(%) -8.2%±5.2% -9.2%±5.2% 0.752
Waist circumference (cm) -9.3±5.9* -10.0±5.8*
(%) -8.5%±5.1% -9.0%±5.3% 0.812
Systolic BP (mmHg) -10±18* -20±22*
(%) -6.6%±12.9% -13.6%±13.7% 0.129
Diastolic BP (mmHg) -5±8* -10±12*
(%) -6.4%±9.1% -11.1%±14.1% 0.223
Fasting glucose (mmol/L) -0.2±0.5 -0.4±0.6*
(%) -2.2%±8.7% -5.9%±10.9% 0.159
HOMA IR -1.0±1.0* -2.3±3.3*
(%) -24.4%±19.6% -31.9%±32.1% 0.229
Triglyceride (mmol/L) -1.5± 3.2* -0.8±0.9*
(%) -32.3%±21.5% -30.9%±28.1% 0.752
Total cholesterol (mmol/L) -0.6±0.9* -0.1±0.6*
(%) -8.3%±13.5% -3.0%±11.2% 0.164
LDL cholesterol (mmol/L) -0.4±0.5* -0.1±0.6
(%) -8.5%±18.0% -2.1%±18.2% 0.206
HDL cholesterol (mmol/L) 0.1±0.1 0.1±0.3
(%) 8.8%±15.2% 8.4%±25.0% 0.899
Serum creatinine -4.5±8.2* 1.6±17.7
(%) -5.2%±9.2% 2.2%±18.0% 0.056
AST (U/L) -7±10* -11±10*
(%) -17.0%±25.0% -28.1%±24.1% 0.129
ALT (U/L) -12±14* -19±13*
(%) -25.6%±27.6% -36.8%±19.6% 0.248
CRP (mg/L) -1.7±4.7* -0.7±2.1
(%) -15.9%±78.1% -1.6%±60.3% 0.343
BDNF (ng/ml) 0.7±1.9 5.7±2.2*
(%) 3.2%±8.8% 31.3%±12.4% <0.001
Zung SDS 2.3±6.7 -3.9±6.2*
(%) 8.8%±23.9% -7.8%±13.9% 0.009
*means P value less than 0.05 intra group.
1 cutoff value: median (16.1%) of the change percentage of BDNF.
ALT = alanine aminotransferase, AST = aspartate aminotransferase,
BDNF = brain-derived neurotrophic factor, BP = blood pressure, CRP = C-reactive
protein, HDL = high-density lipoprotein, HOMA-IR = homeostasis model assessment
of insulin resistance, LDL = low-density lipoprotein, Pc = post-challenge, Zung
SDS = Zung Self-Rating Depression Scale.
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the present study. In fact, serum BDNF was not associated
with fat components of the body [35]. Exercise training
without significant body-weight reduction can also increase
the circulating BDNF concentration [36,37]. It has beenreported recently that only muscle-strengthening, but not
aerobic exercise, could increase circulating BDNF levels in
women [38]. However, the response of BDNF to exercise
might differ between genders [39], and circulating BDNF
levels might be greater after aerobic exercise, rather than
muscle strengthening, in men [40]. Although serum
BDNF change might be correlated with weight-reduction
magnitude in subjects being treated for schizophrenia
[41], the relationship between BDNF and body-weight
might be different due to the influence of gender and
antipsychotic treatment [32,42]. It has been postulated
that the main response of BDNF to exercise originates in
the central nervous system rather than adipose tissue
[43,44]. Therefore, based on our findings, the alteration in
BDNF might not be directly related to the magnitude of
weight reduction in obese men. It has also been reported
that only weight reduction was not capable of improving
depressive symptoms [45].
The proportion of MetS was reported to be significantly
higher in Asian men with depressive symptoms assessed by
Zung SDS than in those without [46]. However, depressive
severity might not be significantly altered with a 5%
reduction in body weight, and may worsen with an
advanced body-weight reduction of 10% [47]. It was
also hypothesized that depression at baseline might
hinder the effect of lifestyle intervention on weight
reduction [48]. However, this hypothesis was not supported
in a previous study on female subjects [49]. Recent
data from the Look Action for Health in Diabetes
(Look AHEAD) study, a large-scale study on lifestyle
intervention, reported that baseline depressive symptoms
did not attenuate the magnitude of weight reduction in
subjects with Type 2 diabetes [50]. In the present study,
neither the baseline condition nor the change in Zung
SDS was correlated with the change in body weight.
Our findings suggest that depressive symptoms do not
attenuate the effect of lifestyle intervention, with a mean
weight reduction of 8.7% in men with MetS.
Among the baseline characteristics assessed in the
present study, only fasting insulin and insulin resistance
(presented by HOMA-IR) were significantly associated with
increase in BDNF. According to previous cross-sectional
studies, insulin sensitivity was associated with circulating
BDNF [30,51], and hyperinsulinemia was a risk factor for
depression [15,52]. Although HOMA-IR was significantly
improved at the end of the present study, the alteration in
HOMA-IR was not significantly different between the
group with a greater BDNF increase and the other. Neither
fasting insulin nor HOMA-IR was significantly correlated
with a reduction in Zung SDS after lifestyle intervention.
The reduction in circulating insulin did not appear to
appreciably improve depressive symptoms even with
functional receptors expressed in the central nervous
system [53]. Based on the other baseline parameters,











r= -0.380, P = 0.022
Figure 1 Relationship between the percentage changes in
BDNF and changes in the Zung Self-Rating Depression Scale
(Zung SDS) score; r = -0.380, P = 0.022.
Table 4 Effects of risk factors on the changes in Zung
Self-Rating Depression Scale during the study
β1 B2 95% CI P
Baseline
Age (years) 0.154 0.102 -0.115 0.319 0.346
HOMA-IR 0.249 0.592 -0.167 1.350 0.122
Change
Body weight (%) 0.209 0.286 -0.155 0.728 0.196
BDNF (%) -0.461 -0.184 -0.315 -0.052 0.008
1β= standardized coefficient, 2B = linear regression coefficient, BDNF= brain-derived
neurotrophic factor, CRP = C-reactive protein, HOMA-IR = homeostasis model
assessment of insulin resistance.
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nificantly different between the subjects with higher
fasting glucose (≥ 5.6 mmol/L) and those with normal
fasting glucose (< 5.6 mmol/L) in the present study.
Furthermore, the alterations in BDNF and Zung SDS
were not significantly different between the subjects
with higher (≥ median of 36.5) and lower (< 36.5)
baseline Zung SDS. The alterations in Zung SDS and
body weight were not significantly different betweenTable 3 Correlations between change in Zung SDS and
percentage change based on different variables after
body weight reduction
r P
Body weight (%) 0.14 0.414
Waist circumference (%) 0.15 0.382
Systolic BP (%) 0.19 0.261
Diastolic BP (%) 0.19 0.279
Fasting glucose (%) -0.11 0.540
Fasting insulin (%) 0.09 0.599
HOMA IR (%) 0.04 0.810
Total cholesterol (%) -0.26 0.128
Triglyceride (%) 0.06 0.736
HDL cholesterol (%) -0.19 0.267
LDL cholesterol (%) 0.19 0.270
Serum creatinine (%) -0.20 0.232
AST (%) 0.02 0.907
ALT (%) 0.08 0.641
CRP (%) -0.09 0.621
ALT = alanine aminotransferase, AST = aspartate aminotransferase,
BDNF = brain-derived neurotrophic factor, BP = blood pressure, CRP = C-reactive
protein, HDL = high-density lipoprotein, HOMA-IR = homeostasis model assessment
of insulin resistance, LDL = low-density lipoprotein, Zung SDS = Zung Self-Rating
Depression Scale.the subjects with higher (≥ median of 40.7 ng/ml) and
lower one (BDNF < 40.7 ng/ml) baseline BDNF. In addition,
our results showed that Zung SDS was not significantly
correlated with inflammation.
Our study shows that the increase in BDNF was
inversely correlated with the severity of depressive
symptoms in men without psychological disorders.
Despite the confounding effect from the open-label
questionnaire answers, the study participants and the
investigators were blinded to the BDNF data during
the study. This finding is noteworthy because BDNF
was found to be involved in the pathogenic mechanism of
depression [44,54]. However, the motivation of enrolled
subjects in a short-term study is usually expected to be
stronger, and the effects of body-weight reduction may be
greater than those in a long-term follow-up. In the Look
AHEAD study, an astonishing reduction in cardiovascular
risks was observed within the first year, but the benefits
were gradually attenuated in the following years [55,56].
With a median follow-up of approximately 10 years,
cardiovascular events were not significantly reduced in the
Look AHEAD study [57]. Therefore, further study on the
long-term effects of lifestyle intervention on BDNF and
depression are warranted.
There were several limitations in the present study.
First, the postprandial change in BDNF by meal test was
not assessed. An increase in free fatty acid was recently
reported to suppress circulating BNDF after a high-fat
intake [58]. However, it was unclear whether the response
of BDNF to fat intake was associated with the depressive
symptoms after body weight reduction. Second, our
findings should only be applied to men. It has recently
been reported that the relationship between circulating
BDNF level and body weight differs between men and
women [59]. There seemed to be a gender difference in
the response of BDNF and depression to body-weight
reduction [32]. Third, the men with increased BDNF
showed a significant decrease in Zung SDS. The assessment
of BDNF appeared to demonstrate that lifestyle interven-
tion had an effect on depression. However, based on the
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ment would ameliorate depressive symptoms or affect
body weight. In addition, cognitive functions or other
psychological disorders were not assessed in the present
study. In consideration of the pleiotropic effects of BDNF
[60,61], it is possible that there were more psychological
benefits for those subjects with increased BDNF after
lifestyle intervention. It has been reported that low
BDNF could predict high mortality in women [62], but its
predictive ability in men requires further long-term studies.
In conclusion, after a 12-week weight reduction
program, a decrease in body weight increased serum
BDNF in obese men with MetS. However, depressive
symptoms, as assessed by Zung SDS, were only signifi-
cantly improved in subjects with increased serum BDNF
levels after lifestyle intervention, independent of changes
in body weight.
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